The Patent Office Need Not Consider Requests for Director Review of IPR Institution Decisions
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
IN RE: PALO ALTO NETWORKS, INC.
Before Dyk, Reyna, and Chen.
Summary: The USPTO policy of refusing to consider Requests for Director Rehearing of decisions denying institution of IPR and PGR does not violate the Appointments Clause of the Constitution.
Palo Alto Networks, Inc. (“PAN”) petitioned for inter parties review (“IPR”) of one patent and post-grant review (“PGR”) of another. While the petitions were pending, the U.S. Patent and Trademark Office (“USPTO”) updated its interim guidance to note that the agency does not accept requests for Director review of institution decisions. The Patent Trial and Appeal Board denied institution of PAN’s IPR and the PGR. PAN filed Requests for Director Rehearing seeking review of the non-institution decisions by the Director, but the USPTO refused to consider the requests. PAN petitioned the Federal Circuit for writ of mandamus, challenging the USPTO policy on which the refusal was based.
Relying on United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021), PAN argued that the USPTO’s categorical refusal to accept requests for Director review of institution decisions violated the Appointments Clause. Arthrex found a violation of the Appointments Clause where the Director—an executive officer appointed by the President—lacked control over final written decisions by administrative patent judges—who are inferior officers not appointed by the President. The Federal Circuit distinguished PAN’s situation from Arthrex because PAN sought review of institution decisions, rather than final written decisions. No structural impediment prevents the Director from reviewing institution decisions, and the Director has occasionally done so sua sponte. Thus, the USPTO’s policy of refusing to consider requests for such review did not violate the Appointments Clause.
Editor: Paul Stewart
Written by: Jeremy Anapol & Brianne M. Kingery
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…